ifenprodil has been researched along with Seizures in 20 studies
ifenprodil: NMDA receptor antagonist
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of our study was to investigate the effects of ifenprodil and MK-801 on D,L-homocysteine thiolactone induced seizures in adult rats." | 7.77 | The effect of N-methyl-D-aspartate receptor antagonists on D,L-homocysteine thiolactone induced seizures in adult rats. ( Djurić, D; Hrnčić, D; Lončar-Stevanović, H; Macut, D; Rašić-Marković, A; Stanojlović, O, 2011) |
| "The aim of our study was to investigate the effects of ifenprodil and MK-801 on D,L-homocysteine thiolactone induced seizures in adult rats." | 3.77 | The effect of N-methyl-D-aspartate receptor antagonists on D,L-homocysteine thiolactone induced seizures in adult rats. ( Djurić, D; Hrnčić, D; Lončar-Stevanović, H; Macut, D; Rašić-Marković, A; Stanojlović, O, 2011) |
| "Pretreatment with ifenprodil resulted in an anticonvulsant effect in 15-day-old rats only, on the contrary, proconvulsant action was found in 18- and 25-day-old animals (decrease of thresholds especially for transition into the second, limbic type of ADs and increase in duration of ADs)." | 1.40 | Age and activation determines the anticonvulsant effect of ifenprodil in rats. ( Mareš, P, 2014) |
| "Using models of acute and chronic seizures in C57BL/6 mice, we discovered a proconvulsant pathway involving high-mobility group box-1 (HMGB1) release from neurons and glia and its interaction with Toll-like receptor 4 (TLR4), a key receptor of innate immunity." | 1.36 | Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. ( Aronica, E; Balosso, S; Bianchi, ME; Casalgrandi, M; Iyer, AM; Liu, J; Manfredi, AA; Maroso, M; Molteni, M; Ravizza, T; Rossetti, C; Vezzani, A, 2010) |
| "Memantine suppressed generalized tonic-clonic seizures in all age groups; minimal seizures were potentiated." | 1.35 | Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. ( Mares, P; Mikulecká, A, 2009) |
| "Ifenprodil is a novel NMDA receptor antagonist that selectively inhibits receptors containing the NR2B subunit." | 1.35 | Influence of NR2B-selective NMDA antagonist on lindane-induced seizures in rats. ( Djurić, D; Hrncić, D; Rasić-Marković, A; Stanojlović, O; Susić, V, 2009) |
| "With the use of well defined animal seizure models, Con-R was found to possess an anticonvulsant profile superior to that of ifenprodil and dizocilpine (MK-801)." | 1.31 | In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. ( Abogadie, FC; Armstrong, H; Cruz, LJ; Donevan, SD; Hollmann, M; McCabe, RT; Olivera, BM; Paarmann, I; Rivier, JE; Torres, J; White, HS, 2000) |
| "Rats become susceptible to audiogenic seizures (AS) when they are exposed to intense noise during a certain critical period of development (priming)." | 1.31 | Effects of N-methyl-D-aspartate receptor subunit antagonists on regulation of susceptibility to audiogenic seizures in rats. ( Hironaka, N; Niki, H, 2000) |
| "Furthermore, the seizure threshold of DMCM was increased by intracerebroventricular (i." | 1.30 | Role of the NMDA receptor complex in DMCM-induced seizure in mice. ( Misawa, M; Suzuki, T; Tsuda, M, 1997) |
| "The decrease in the seizure threshold for pentylenetetrazole during diazepam withdrawal was inhibited by pretreatment with MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cycloheptan-5,10-imine maleate), 7-chlorokynurenic acid and ifenprodil." | 1.30 | Recovery of decreased seizure threshold for pentylenetetrazole during diazepam withdrawal by NMDA receptor antagonists. ( Misawa, M; Suzuki, T; Tsuda, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okuda, K | 1 |
| Kobayashi, S | 1 |
| Fukaya, M | 1 |
| Watanabe, A | 1 |
| Murakami, T | 1 |
| Hagiwara, M | 1 |
| Sato, T | 1 |
| Ueno, H | 1 |
| Ogonuki, N | 1 |
| Komano-Inoue, S | 1 |
| Manabe, H | 1 |
| Yamaguchi, M | 1 |
| Ogura, A | 1 |
| Asahara, H | 1 |
| Sakagami, H | 1 |
| Mizuguchi, M | 1 |
| Manabe, T | 1 |
| Tanaka, T | 1 |
| Mareš, P | 2 |
| Mikulecká, A | 1 |
| Hrncić, D | 2 |
| Rasić-Marković, A | 2 |
| Susić, V | 1 |
| Djurić, D | 2 |
| Stanojlović, O | 2 |
| Maroso, M | 1 |
| Balosso, S | 1 |
| Ravizza, T | 1 |
| Liu, J | 1 |
| Aronica, E | 1 |
| Iyer, AM | 1 |
| Rossetti, C | 1 |
| Molteni, M | 1 |
| Casalgrandi, M | 1 |
| Manfredi, AA | 1 |
| Bianchi, ME | 1 |
| Vezzani, A | 1 |
| Macut, D | 1 |
| Lončar-Stevanović, H | 1 |
| D'Hooge, R | 1 |
| Van de Vijver, G | 1 |
| Van Bogaert, PP | 1 |
| Marescau, B | 1 |
| Vanholder, R | 1 |
| De Deyn, PP | 1 |
| Kaasinen, SK | 1 |
| Gröhn, OH | 1 |
| Keinänen, TA | 1 |
| Alhonen, L | 1 |
| Jänne, J | 1 |
| Bandyopadhyay, S | 1 |
| Hablitz, JJ | 1 |
| Shin, EJ | 1 |
| Nah, SY | 1 |
| Chae, JS | 1 |
| Bing, G | 1 |
| Shin, SW | 1 |
| Yen, TP | 1 |
| Baek, IH | 1 |
| Kim, WK | 1 |
| Maurice, T | 1 |
| Nabeshima, T | 1 |
| Kim, HC | 1 |
| De Sarro, G | 1 |
| Ammendola, D | 1 |
| Nava, F | 1 |
| De Sarro, A | 1 |
| Zarnowski, T | 1 |
| Kleinrok, Z | 1 |
| Turski, WA | 1 |
| Czuczwar, SJ | 1 |
| Doyle, KM | 1 |
| Shaw, GG | 1 |
| Tsuda, M | 2 |
| Suzuki, T | 2 |
| Misawa, M | 2 |
| Yourick, DL | 1 |
| Repasi, RT | 1 |
| Rittase, WB | 1 |
| Staten, LD | 1 |
| Meyerhoff, JL | 1 |
| Malinowska, B | 1 |
| Napiórkowska-Pawlak, D | 1 |
| Pawlak, R | 1 |
| Buczko, W | 1 |
| Göthert, M | 1 |
| White, HS | 1 |
| McCabe, RT | 1 |
| Armstrong, H | 1 |
| Donevan, SD | 1 |
| Cruz, LJ | 1 |
| Abogadie, FC | 1 |
| Torres, J | 1 |
| Rivier, JE | 1 |
| Paarmann, I | 1 |
| Hollmann, M | 1 |
| Olivera, BM | 1 |
| Hironaka, N | 1 |
| Niki, H | 1 |
| Pontecorvo, MJ | 1 |
| Karbon, EW | 1 |
| Goode, S | 1 |
| Clissold, DB | 1 |
| Borosky, SA | 1 |
| Patch, RJ | 1 |
| Ferkany, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
20 other studies available for ifenprodil and Seizures
| Article | Year |
|---|---|
CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility.
Topics: Animals; Disease Models, Animal; Disease Susceptibility; Excitatory Amino Acid Antagonists; Guanylat | 2017 |
Age and activation determines the anticonvulsant effect of ifenprodil in rats.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Electric Stimulation; Male; Pentylenetetrazole; P | 2014 |
Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Convulsants; Dose-Response Relationship, Drug; Epilepsy, | 2009 |
Influence of NR2B-selective NMDA antagonist on lindane-induced seizures in rats.
Topics: Animals; Dose-Response Relationship, Drug; Drug Interactions; Electroencephalography; Excitatory Ami | 2009 |
Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Hippoc | 2010 |
The effect of N-methyl-D-aspartate receptor antagonists on D,L-homocysteine thiolactone induced seizures in adult rats.
Topics: Animals; Dizocilpine Maleate; Homocysteine; Male; Piperidines; Rats; Rats, Wistar; Receptors, N-Meth | 2011 |
Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Bicuculline; Calcium Cha | 2003 |
Overexpression of spermidine/spermine N1-acetyltransferase elevates the threshold to pentylenetetrazol-induced seizure activity in transgenic mice.
Topics: Acetyltransferases; Animals; Biogenic Polyamines; Brain; Cell Count; Crosses, Genetic; Dose-Response | 2003 |
NR2B antagonists restrict spatiotemporal spread of activity in a rat model of cortical dysplasia.
Topics: Adrenergic alpha-Antagonists; Animals; Disease Models, Animal; Evoked Potentials; Neocortex; Patch-C | 2006 |
Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats.
Topics: Adrenergic alpha-Antagonists; Animals; Avoidance Learning; Behavior, Animal; Dextromethorphan; Ethyl | 2007 |
Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Amino Acids; Animals; Anticonvuls | 1995 |
The NMDA antagonist procyclidine, but not ifenprodil, enhances the protective efficacy of common antiepileptics against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Drug Synergism; Electroshock; Male; Memory; Mice; Move | 1994 |
Investigation of the involvement of the N-methyl-D-aspartate receptor macrocomplex in the development of spermine-induced CNS excitation in vivo.
Topics: Animals; Brain; Cerebral Ventricles; Dizocilpine Maleate; Female; Kynurenic Acid; Mice; Neuroprotect | 1996 |
Role of the NMDA receptor complex in DMCM-induced seizure in mice.
Topics: Animals; Carbolines; Cerebral Ventricles; Convulsants; Dizocilpine Maleate; Excitatory Amino Acid An | 1997 |
Recovery of decreased seizure threshold for pentylenetetrazole during diazepam withdrawal by NMDA receptor antagonists.
Topics: Animals; Anticonvulsants; Convulsants; Diazepam; Disease Models, Animal; Dizocilpine Maleate; Drug I | 1997 |
Ifenprodil and arcaine alter amygdala-kindling development.
Topics: Amygdala; Animals; Anticonvulsants; Biguanides; Brain; Dose-Response Relationship, Drug; Electric St | 1999 |
Ifenprodil influences changes in mouse behaviour related to acute and chronic ethanol administration.
Topics: Animals; Behavior, Animal; Brain; Central Nervous System Depressants; Dose-Response Relationship, Dr | 1999 |
In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus.
Topics: Animals; Anticonvulsants; Behavior, Animal; Binding, Competitive; Cerebral Cortex; Conotoxins; Dizoc | 2000 |
Effects of N-methyl-D-aspartate receptor subunit antagonists on regulation of susceptibility to audiogenic seizures in rats.
Topics: Animals; Dextromethorphan; Disease Susceptibility; Epilepsy, Reflex; Excitatory Amino Acid Antagonis | 2000 |
Possible cerebroprotective and in vivo NMDA antagonist activities of sigma agents.
Topics: Animals; Anticonvulsants; Brain Diseases; Electroshock; Haloperidol; Hypoxia; Male; Mice; Mice, Inbr | 1991 |